Consonance Capital Management is Fond of Healthcare Stocks

Consonance Capital Management is a New York based hedge fund established in 2005, managed by Mitchell Blutt MD. The firm usually invests in the lower middle market, in value stocks of small and mid-cap companies, focusing on the healthcare sector (payors, pharmaceutical, specialty distributors, and device manufacturers). CEO Mitchell Blutt uses his medical training and knowledge to identify attractive investment opportunities, companies with potential, within this segment. Before founding Consonance Capital, Mr. Blutt worked as Executive Partner at J.P. Morgan Partners.

A few days ago, the fund filed a Form 13F at the SEC, disclosing its long equity positions as of March 31 2014. It declared holding 37 different positions, all of them in the healthcare sector. Newcommers in the portfolio were represented by 10 of these holdings, and another 14 saw the fund increase its stakes over the quarter. Let’s take a closer look at the top holdings in this portfolio, valued at more than $672 million, and some of the moves that took place over Q1.

United Therapeutics Corporation (NASDAQ:UTHR)

Mr. Blutt’s top position remained the same: United Therapeutics Corporation (NASDAQ:UTHR). In fact, this $4.8 billion market cap biotechnology company saw the fund’s stakes increase by 15% over Q1. Consonance now owns 669,690 shares of the company, worth more than $67 million, which accounts for more than 9% of the total value of its equity portfolio. This makes it the second largest hedge fund shareholder, only trailing William Leland Edwards’ Palo Alto Investors, which owns 1.1 million shares.

The second place was occupied by a new stock in Consonance’s equity portfolio: Myriad Genetics, Inc. (NASDAQ:MYGN), a $2.5 billion market cap company engaged in the discovery and commercialization of transformative tests which assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Over the first quarter, Mr. Blutt’s fund acquired 1.74 million shares, valued at approximately $58 million. However, this stake becomes quite small when compared to Royce & Associates’. The fund managed by Chuck Royce owns about $314 million in the company’s stock.

Furiex Pharmaceuticals Inc (NASDAQ:FURX) is the only one of Consonance’s top five positions for Q1 that saw a decrease in its stakes. However, the bet placed on this $1.1 billion market cap drug development collaborate company is still quite big: 616,495 shares, worth about $64 million. This position makes Consonace the largest hedge fund shareholder at the company. Second in rank, with about half the shares (376,365), is Israel Englander’s Millennium Management.

Back to bullish moves, we have Enanta Pharmaceuticals Inc (NASDAQ:ENTA), a $716 million market cap research and development focused biotechnology company. In its last 13F, Consonance disclosed ownership of 1.25 million shares (up 47% in relation to Q4), valued at roughly $48 million. Once again, Mr. Blutt’s fund is the company’s largest hedge fund stockholder

Finally, there’s BioScrip Inc (NASDAQ:BIOS), a $505 million market cap provider of home infusion and other home healthcare services. Over the quarter, the fund acquired 1.1 million shares, and now owns more than 5 million of them. This position, worth about $37 million, makes of the fund, yet again, the largest hedge fund investor, trailed, for a second time, by Englander’s Millennium Management, with 2.1 million shares.

Disclosure: Javier Hasse holds no position in any stocks mentioned.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!